Researchers have reported that individuals undergoing CAR T-cell therapy for blood cancers are at risk of neurological side effects; categorizing and understanding these side effects could be important in future diagnosis and treatment.
Browsing: side effects
Over a third of adults in the USA may be unknowingly using prescription medications that could increase the risk of depression and suicide.
A team of researchers have developed a wearable belt technology which could be utilized to support rehabilitation for Parkinson’s patients via biofeedback. The technology can also be potentially utilized in the management of elderly people who also suffer from balance issues.
In this review, the authors highlight the recent progress in TD genetic research with a particular focus since 2011. They review genes involved in antipsychotic drug metabolism (pharmacokinetics) and those involved in drug targeting (pharmacodynamics), and provide a number of recommendations to move this area of research forward.
The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson’s disease treatment
The use of dopamine agonists for Parkinson’s treatment is often associated with unwanted side effects. This review identifies strategies for managing or avoiding these effects and discusses future needs to improve the understanding of these phenomena.
This article discusses the clinical presentation and diagnosis of germinomas as well as current management and key considerations.
Pietro Gareri from The Regional Center for Neurogenetics at Lamezia Terme Hospital (Catanzaro, Italy) discusses the future of the use of antipsychotics to manage behavior in dementia patients.
Agranulocytosis is a severe potential side effect for schizophrenic patients precribed clozapine, meaning close montioring with invasive white blood cell counts is required. This article discusses the potential of pharmacogenomics as an alternative for evaluating patients at low or high risk of developing the condition.
Preclinical findings have identified novel compounds – GABA-NAMs – that are able to reduce inhibitory communication in the brain and may hold the potential to rapidly treat depression
This review provides an overview of the potential role of pharmacogenomics in predisposing a child to unhealthy weight gain and cardiometabolic side effects with SGA treatment.